Are you over 18 and want to see adult content?
More Annotations
![A complete backup of www.news.com.au/sport/football/sickening-tackle-goes-unpunished-in-chelsea-vs-tottenham-game/news-story/da7](https://www.archivebay.com/archive2/ac3ae491-168f-4762-bebe-803dbce1a3d5.png)
A complete backup of www.news.com.au/sport/football/sickening-tackle-goes-unpunished-in-chelsea-vs-tottenham-game/news-story/da7
Are you over 18 and want to see adult content?
![A complete backup of sport.se.pl/pilka-nozna/ekstraklasa/lks-lodz-pogon-szczecin-kolejna-kompromitacja-przy-karnym-portowcy-zgub](https://www.archivebay.com/archive2/08b64002-b309-4d95-a3a8-af1e55505ed7.png)
A complete backup of sport.se.pl/pilka-nozna/ekstraklasa/lks-lodz-pogon-szczecin-kolejna-kompromitacja-przy-karnym-portowcy-zgub
Are you over 18 and want to see adult content?
Favourite Annotations
![A complete backup of repeliscom2c.blogspot.com](https://www.archivebay.com/archive2/c964b7d4-8808-4524-b744-a30c8cfed624.png)
A complete backup of repeliscom2c.blogspot.com
Are you over 18 and want to see adult content?
![A complete backup of theenergycase.com](https://www.archivebay.com/archive2/bd7f5eb1-2719-470d-8709-b4131ab2d81b.png)
A complete backup of theenergycase.com
Are you over 18 and want to see adult content?
Text
analysts.
AC IMMUNE | CAREER OPPORTUNITIES AC Immune biopharmaceutical company developing innovative therapeutics with \'best in class\' potential against Alzheimer´s Disease and other conformational diseases along three axes: vaccines, antibodies and small molecules. SYNUCLEIN PET PROJECT REPRINT FROM FEBRUARY 28, 2019 TOOLS & TECHNIQUES Synuclein PET project BY ALLISON JOHNSON, STAFF WRITER As the Parkinson’s field starts to solve the problem of how to 2021 GLOBAL DOWN SYNDROME FORUM The Investor Relations website contains information about AC Immune SA's business for stockholders, potential investors, and financialanalysts.
SMALL MOLECULES TARGETING TAU PROPAGATION … Sonia Poli is an AC Immune’s employee No off-label nor investigational use of therapeutic products will be presented DEVELOPMENT OF HIGHLY SENSITIVE MSD ASSAYS FOR THE Development of Highly Sensitive MSD Assays for the Detection of anti-A. β. Antibodies Specific for Different Pathological A. β-species and A. β - peptide on AC IMMUNE INITIATES PHASE 1 STUDY OF ACI-3024 SMALL Tau Morphomer™ is the focus of a partnership with Eli Lilly and Company. LAUSANNE, Switzerland, July 17, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, today announced dosing of the first subject in a Phase 1 study of ACI-3024, a first-in-class investigational oral small molecule Tau Morphomer™ inhibitor that will be AC IMMUNEABOUT USSCIENCEPIPELINEINVESTORSJOIN USCONTACT US AC Immune biopharmaceutical company developing innovative therapeutics with \'best in class\' potential against Alzheimer´s Disease and other conformational diseases along three axes: vaccines, antibodies and small molecules. AC IMMUNE | AC IMMUNE'S ROBUST PIPELINE AC Immune biopharmaceutical company developing innovative therapeutics with \'best in class\' potential against Alzheimer´s Disease and other conformational diseases along three axes: vaccines, antibodies and small molecules. AC IMMUNE | INVESTORS AC Immune biopharmaceutical company developing innovative therapeutics with \'best in class\' potential against Alzheimer´s Disease and other conformational diseases along three axes: vaccines, antibodies and small molecules. OVERVIEW | AC IMMUNE SA The Investor Relations website contains information about AC Immune SA's business for stockholders, potential investors, and financialanalysts.
AC IMMUNE | CAREER OPPORTUNITIES AC Immune biopharmaceutical company developing innovative therapeutics with \'best in class\' potential against Alzheimer´s Disease and other conformational diseases along three axes: vaccines, antibodies and small molecules. SYNUCLEIN PET PROJECT REPRINT FROM FEBRUARY 28, 2019 TOOLS & TECHNIQUES Synuclein PET project BY ALLISON JOHNSON, STAFF WRITER As the Parkinson’s field starts to solve the problem of how to 2021 GLOBAL DOWN SYNDROME FORUM The Investor Relations website contains information about AC Immune SA's business for stockholders, potential investors, and financialanalysts.
SMALL MOLECULES TARGETING TAU PROPAGATION … Sonia Poli is an AC Immune’s employee No off-label nor investigational use of therapeutic products will be presented DEVELOPMENT OF HIGHLY SENSITIVE MSD ASSAYS FOR THE Development of Highly Sensitive MSD Assays for the Detection of anti-A. β. Antibodies Specific for Different Pathological A. β-species and A. β - peptide on AC IMMUNE INITIATES PHASE 1 STUDY OF ACI-3024 SMALL Tau Morphomer™ is the focus of a partnership with Eli Lilly and Company. LAUSANNE, Switzerland, July 17, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, today announced dosing of the first subject in a Phase 1 study of ACI-3024, a first-in-class investigational oral small molecule Tau Morphomer™ inhibitor that will be OVERVIEW | AC IMMUNE SA The Investor Relations website contains information about AC Immune SA's business for stockholders, potential investors, and financialanalysts.
AC IMMUNE | CAREER OPPORTUNITIES AC Immune biopharmaceutical company developing innovative therapeutics with \'best in class\' potential against Alzheimer´s Disease and other conformational diseases along three axes: vaccines, antibodies and small molecules. AC IMMUNE | TECHNOLOGY PLATFORMS Our two proprietary technology platforms are product focused and highly productive engines for the sustained growth of our Company. Our biological SupraAntigen TM and chemical Morphomer TM platforms are our scientific basis to generate a robust pipeline of antibodies, vaccines and small molecules which selectively bind to misfolded proteins representing the underlying causes of a broad AC IMMUNE | SCIENTIFIC PUBLICATIONS AC Immune biopharmaceutical company developing innovative therapeutics with \'best in class\' potential against Alzheimer´s Disease and other conformational diseases along three axes: vaccines, antibodies and small molecules. AC IMMUNE | BOARD OF DIRECTORS Martin Velasco is an entrepreneur and Business Angel with extensive experience in the IT medical and biotech areas. He serves on the board of directors or advisory board of several other high-tech companies including: as Founder, Chairman and Chief Executive Officer of Anecova, an assisted reproductive technology (ART) company and World Economic Forum Technology Pioneer 2008, as AC IMMUNE PROVIDES UPDATE ON ALZHEIMER’S DISEASE VACCINE Optimized vaccine candidate generates enhanced polyclonal antibody response against pyroglutamate Abeta in non-human primates. Phase 2 interim analysis of ACI-24 confirms good safety and tolerability profile in people with mild Alzheimer’s disease PRINCIPAL TOXICOLOGIST Principal Toxicologist Description Function Principal toxicologist Location / Contact AC Immune SA, EPFL Innovation Park, Building B, 1015 Lausanne hr@acimmune.com Percentage 100 % - available immediately Reporting Line Group Leader, in vivo pharmacology and non-clinical safety Company Profile • AC Immune is a clinical stage Swiss biotech company focused on the STRUCTURE OF CRENEZUMAB COMPLEX WITH AΒ SHOWS LOSS OF Β SCIENTIFIC REPORTS 4 I 1.1srep4 1 www.nature.comscientificreports Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin Mark Ultsch1, Bing Li1, Till Maurer1, Mary Mathieu1, Oskar Adolfsson2, Andreas Muhs2, Andrea Pfeifer2, Maria Pihlgren2, Travis W. Bainbridge1, Mike Reichelt1, James A. Ernst1, Charles Eigenbrot1, Germaine Fuh1, Jasvinder K. Atwal1, Ryan J. Watts1 & Weiru Wang1 BINDING AFFINITY MEASUREMENT OF ANTIBODIES FROM CRUDE the contact time of the dissociation phase should be long enough to have a flat sensorgram after dissociation phase. After association and dissociation of the analyte, a regeneration step was performed in order to remove the remaining AC IMMUNE ANNOUNCES APPOINTMENT OF DR. MARIE KOSCO-VILBOIS Lausanne, Switzerland, January 3, 2019 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on Neurodegenerative Diseases, today announced that it has appointed Dr. Marie Kosco-Vilbois, as Chief Scientific Officer, effective January 3, 2019.. Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: "I am delighted to welcome AC IMMUNEABOUT USSCIENCEPIPELINEINVESTORSJOIN USCONTACT US AC Immune. At AC Immune, we are passionate about making a difference in the lives of people affected by Alzheimer’s and other neurodegenerative diseases. Our goal is to become the global leader in precision medicine of neurodegenerative diseases that are one of the biggest challenges facing society today and future generations. AC IMMUNE | AC IMMUNE'S ROBUST PIPELINE AC Immune's robust pipeline. Our robust and diverse pipeline of nine therapeutic and three diagnostic product candidates has the potential to greatly improve the treatment of a broad spectrum of Alzheimer’s and neurodegenerative diseases. All of the company’s products were discovered utilizing its proprietary SupraAntigen™ and Morphomer OVERVIEW | AC IMMUNE SA LAUSANNE , Switzerland , May 20, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will participate in the UBS Global Healthcare Virtual Conference and the Jefferies. PDF Version 124 KB. May 17, 2021.Summary Toggle.
AC IMMUNE | INVESTORS AC Immune’s investors are knowledgeable about life sciences and share the company’s commitment to developing state of the art solutions to the treatment of neurodegenerative diseases. Their oversight, guidance and support have proved an invaluable resource to AC Immune’s management. Together we have sought to make the mostefficient and
AC IMMUNE | CONTACT US AC Immune biopharmaceutical company developing innovative therapeutics with \'best in class\' potential against Alzheimer´s Disease and other conformational diseases along three axes: vaccines, antibodies and small molecules. AC IMMUNE PROVIDES UPDATE ON ALZHEIMER’S DISEASE VACCINE Optimized vaccine candidate generates enhanced polyclonal antibody response against pyroglutamate Abeta in non-human primates. Phase 2 interim analysis of ACI-24 confirms good safety and tolerability profile in people with mild Alzheimer’s disease AC IMMUNE | SENIOR MANAGEMENT TEAM AC Immune’s leadership team combines a proven track record in entrepreneurial management and world-class scientific thought leadership. The team is committed to excellence and is passionate about delivering breakthrough therapies for neurodegenerativediseases.
2021 GLOBAL DOWN SYNDROME FORUM The Investor Relations website contains information about AC Immune SA's business for stockholders, potential investors, and financialanalysts.
IDENTIFICATION AND CHARACTERIZATION OF SELECTIVE AND … March, 2019 © 2019 AC Immune. Not to be used or reproduced without permission. 3 >90% of PD cases are sporadic: diagnosis can not be achieved by genetic testing STRUCTURE OF CRENEZUMAB COMPLEX WITH AΒ SHOWS LOSS OF Β SCIENTIFIC REPORTS 4 I 1.1srep4 1 www.nature.comscientificreports Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin Mark Ultsch1, Bing Li1, Till Maurer1, Mary Mathieu1, Oskar Adolfsson2, Andreas Muhs2, Andrea Pfeifer2, Maria Pihlgren2, Travis W. Bainbridge1, Mike Reichelt1, James A. Ernst1, Charles Eigenbrot1, Germaine Fuh1, Jasvinder K. Atwal1, Ryan J. Watts1 & Weiru Wang1 AC IMMUNEABOUT USSCIENCEPIPELINEINVESTORSJOIN USCONTACT US AC Immune. At AC Immune, we are passionate about making a difference in the lives of people affected by Alzheimer’s and other neurodegenerative diseases. Our goal is to become the global leader in precision medicine of neurodegenerative diseases that are one of the biggest challenges facing society today and future generations. AC IMMUNE | AC IMMUNE'S ROBUST PIPELINE AC Immune's robust pipeline. Our robust and diverse pipeline of nine therapeutic and three diagnostic product candidates has the potential to greatly improve the treatment of a broad spectrum of Alzheimer’s and neurodegenerative diseases. All of the company’s products were discovered utilizing its proprietary SupraAntigen™ and Morphomer OVERVIEW | AC IMMUNE SA LAUSANNE , Switzerland , May 20, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will participate in the UBS Global Healthcare Virtual Conference and the Jefferies. PDF Version 124 KB. May 17, 2021.Summary Toggle.
AC IMMUNE | INVESTORS AC Immune’s investors are knowledgeable about life sciences and share the company’s commitment to developing state of the art solutions to the treatment of neurodegenerative diseases. Their oversight, guidance and support have proved an invaluable resource to AC Immune’s management. Together we have sought to make the mostefficient and
AC IMMUNE | CONTACT US AC Immune biopharmaceutical company developing innovative therapeutics with \'best in class\' potential against Alzheimer´s Disease and other conformational diseases along three axes: vaccines, antibodies and small molecules. AC IMMUNE PROVIDES UPDATE ON ALZHEIMER’S DISEASE VACCINE Optimized vaccine candidate generates enhanced polyclonal antibody response against pyroglutamate Abeta in non-human primates. Phase 2 interim analysis of ACI-24 confirms good safety and tolerability profile in people with mild Alzheimer’s disease AC IMMUNE | SENIOR MANAGEMENT TEAM AC Immune’s leadership team combines a proven track record in entrepreneurial management and world-class scientific thought leadership. The team is committed to excellence and is passionate about delivering breakthrough therapies for neurodegenerativediseases.
2021 GLOBAL DOWN SYNDROME FORUM The Investor Relations website contains information about AC Immune SA's business for stockholders, potential investors, and financialanalysts.
IDENTIFICATION AND CHARACTERIZATION OF SELECTIVE AND … March, 2019 © 2019 AC Immune. Not to be used or reproduced without permission. 3 >90% of PD cases are sporadic: diagnosis can not be achieved by genetic testing STRUCTURE OF CRENEZUMAB COMPLEX WITH AΒ SHOWS LOSS OF Β SCIENTIFIC REPORTS 4 I 1.1srep4 1 www.nature.comscientificreports Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin Mark Ultsch1, Bing Li1, Till Maurer1, Mary Mathieu1, Oskar Adolfsson2, Andreas Muhs2, Andrea Pfeifer2, Maria Pihlgren2, Travis W. Bainbridge1, Mike Reichelt1, James A. Ernst1, Charles Eigenbrot1, Germaine Fuh1, Jasvinder K. Atwal1, Ryan J. Watts1 & Weiru Wang1 AC IMMUNE | TECHNOLOGY PLATFORMS Our two proprietary technology platforms are product focused and highly productive engines for the sustained growth of our Company. Our biological SupraAntigen TM and chemical Morphomer TM platforms are our scientific basis to generate a robust pipeline of antibodies, vaccines and small molecules which selectively bind to misfolded proteins representing the underlying causes of a broad AC IMMUNE | ALZHEIMER'S DISEASE AC Immune’s therapeutic and diagnostic agents are at the forefront of fighting against one of the world’s greatest healthcare challenges – the need to develop reliable and accurate diagnostics and disease modifying treatments to improve the lives of patients suffering from Alzheimer’s and other neurodegenerative diseases. AC IMMUNE | SENIOR MANAGEMENT TEAM AC Immune’s leadership team combines a proven track record in entrepreneurial management and world-class scientific thought leadership. The team is committed to excellence and is passionate about delivering breakthrough therapies for neurodegenerativediseases.
NEWS | AC IMMUNE SA
The Investor Relations website contains information about AC Immune SA's business for stockholders, potential investors, and financialanalysts.
AC IMMUNE DEMONSTRATES ENHANCED PERFORMANCE OF FIRST-IN AC Immune Demonstrates Enhanced Performance of First-in-class Parkinson s Diagnostic Agent July 28, 2020 Next-generation PET tracer detects pathological alpha-synuclein with improved signal-to-noiseratio
SMALL MOLECULES TARGETING TAU PROPAGATION … Sonia Poli is an AC Immune’s employee No off-label nor investigational use of therapeutic products will be presented AC IMMUNE INITIATES PHASE 1 STUDY OF ACI-3024 SMALL Tau Morphomer™ is the focus of a partnership with Eli Lilly and Company. LAUSANNE, Switzerland, July 17, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, today announced dosing of the first subject in a Phase 1 study of ACI-3024, a first-in-class investigational oral small molecule Tau Morphomer™ inhibitor that will be SYNUCLEIN PET PROJECT REPRINT FROM FEBRUARY 28, 2019 TOOLS & TECHNIQUES Synuclein PET project BY ALLISON JOHNSON, STAFF WRITER As the Parkinson’s field starts to solve the problem of how to DEVELOPMENT OF HIGHLY SENSITIVE MSD ASSAYS FOR THE Development of Highly Sensitive MSD Assays for the Detection of anti-A. β. Antibodies Specific for Different Pathological A. β-species and A. β - peptide on MORPHOMER : PLATFORM AND PIPELINE REVIEW NASDAQ: ACIU | Morphomer™Platform Event | March 2021 © 2021 AC Immune. Not to be used or reproduced without permission 2013 2014 20152017 2019
AC IMMUNEABOUT USSCIENCEPIPELINEINVESTORSJOIN USCONTACT US AC Immune. At AC Immune, we are passionate about making a difference in the lives of people affected by Alzheimer’s and other neurodegenerative diseases. Our goal is to become the global leader in precision medicine of neurodegenerative diseases that are one of the biggest challenges facing society today and future generations. AC IMMUNE | AC IMMUNE'S ROBUST PIPELINE AC Immune's robust pipeline. Our robust and diverse pipeline of nine therapeutic and three diagnostic product candidates has the potential to greatly improve the treatment of a broad spectrum of Alzheimer’s and neurodegenerative diseases. All of the company’s products were discovered utilizing its proprietary SupraAntigen™ and Morphomer AC IMMUNE | INVESTORS AC Immune’s investors are knowledgeable about life sciences and share the company’s commitment to developing state of the art solutions to the treatment of neurodegenerative diseases. Their oversight, guidance and support have proved an invaluable resource to AC Immune’s management. Together we have sought to make the mostefficient and
OVERVIEW | AC IMMUNE SA LAUSANNE , Switzerland , May 20, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will participate in the UBS Global Healthcare Virtual Conference and the Jefferies. PDF Version 124 KB. May 17, 2021.Summary Toggle.
AC IMMUNE | TECHNOLOGY PLATFORMS Our two proprietary technology platforms are product focused and highly productive engines for the sustained growth of our Company. Our biological SupraAntigen TM and chemical Morphomer TM platforms are our scientific basis to generate a robust pipeline of antibodies, vaccines and small molecules which selectively bind to misfolded proteins representing the underlying causes of a broad AC IMMUNE | CONTACT US AC Immune biopharmaceutical company developing innovative therapeutics with \'best in class\' potential against Alzheimer´s Disease and other conformational diseases along three axes: vaccines, antibodies and small molecules. AC IMMUNE | SENIOR MANAGEMENT TEAM AC Immune’s leadership team combines a proven track record in entrepreneurial management and world-class scientific thought leadership. The team is committed to excellence and is passionate about delivering breakthrough therapies for neurodegenerativediseases.
AC IMMUNE PROVIDES UPDATE ON ALZHEIMER’S DISEASE VACCINE Optimized vaccine candidate generates enhanced polyclonal antibody response against pyroglutamate Abeta in non-human primates. Phase 2 interim analysis of ACI-24 confirms good safety and tolerability profile in people with mild Alzheimer’s disease 2021 GLOBAL DOWN SYNDROME FORUM The Investor Relations website contains information about AC Immune SA's business for stockholders, potential investors, and financialanalysts.
STRUCTURE OF CRENEZUMAB COMPLEX WITH AΒ SHOWS LOSS OF Β SCIENTIFIC REPORTS 4 I 1.1srep4 1 www.nature.comscientificreports Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin Mark Ultsch1, Bing Li1, Till Maurer1, Mary Mathieu1, Oskar Adolfsson2, Andreas Muhs2, Andrea Pfeifer2, Maria Pihlgren2, Travis W. Bainbridge1, Mike Reichelt1, James A. Ernst1, Charles Eigenbrot1, Germaine Fuh1, Jasvinder K. Atwal1, Ryan J. Watts1 & Weiru Wang1 AC IMMUNEABOUT USSCIENCEPIPELINEINVESTORSJOIN USCONTACT US AC Immune. At AC Immune, we are passionate about making a difference in the lives of people affected by Alzheimer’s and other neurodegenerative diseases. Our goal is to become the global leader in precision medicine of neurodegenerative diseases that are one of the biggest challenges facing society today and future generations. AC IMMUNE | AC IMMUNE'S ROBUST PIPELINE AC Immune's robust pipeline. Our robust and diverse pipeline of nine therapeutic and three diagnostic product candidates has the potential to greatly improve the treatment of a broad spectrum of Alzheimer’s and neurodegenerative diseases. All of the company’s products were discovered utilizing its proprietary SupraAntigen™ and Morphomer AC IMMUNE | INVESTORS AC Immune’s investors are knowledgeable about life sciences and share the company’s commitment to developing state of the art solutions to the treatment of neurodegenerative diseases. Their oversight, guidance and support have proved an invaluable resource to AC Immune’s management. Together we have sought to make the mostefficient and
OVERVIEW | AC IMMUNE SA LAUSANNE , Switzerland , May 20, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will participate in the UBS Global Healthcare Virtual Conference and the Jefferies. PDF Version 124 KB. May 17, 2021.Summary Toggle.
AC IMMUNE | TECHNOLOGY PLATFORMS Our two proprietary technology platforms are product focused and highly productive engines for the sustained growth of our Company. Our biological SupraAntigen TM and chemical Morphomer TM platforms are our scientific basis to generate a robust pipeline of antibodies, vaccines and small molecules which selectively bind to misfolded proteins representing the underlying causes of a broad AC IMMUNE | CONTACT US AC Immune biopharmaceutical company developing innovative therapeutics with \'best in class\' potential against Alzheimer´s Disease and other conformational diseases along three axes: vaccines, antibodies and small molecules. AC IMMUNE | SENIOR MANAGEMENT TEAM AC Immune’s leadership team combines a proven track record in entrepreneurial management and world-class scientific thought leadership. The team is committed to excellence and is passionate about delivering breakthrough therapies for neurodegenerativediseases.
AC IMMUNE PROVIDES UPDATE ON ALZHEIMER’S DISEASE VACCINE Optimized vaccine candidate generates enhanced polyclonal antibody response against pyroglutamate Abeta in non-human primates. Phase 2 interim analysis of ACI-24 confirms good safety and tolerability profile in people with mild Alzheimer’s disease 2021 GLOBAL DOWN SYNDROME FORUM The Investor Relations website contains information about AC Immune SA's business for stockholders, potential investors, and financialanalysts.
STRUCTURE OF CRENEZUMAB COMPLEX WITH AΒ SHOWS LOSS OF Β SCIENTIFIC REPORTS 4 I 1.1srep4 1 www.nature.comscientificreports Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin Mark Ultsch1, Bing Li1, Till Maurer1, Mary Mathieu1, Oskar Adolfsson2, Andreas Muhs2, Andrea Pfeifer2, Maria Pihlgren2, Travis W. Bainbridge1, Mike Reichelt1, James A. Ernst1, Charles Eigenbrot1, Germaine Fuh1, Jasvinder K. Atwal1, Ryan J. Watts1 & Weiru Wang1 AC IMMUNE | CONTACT US AC Immune biopharmaceutical company developing innovative therapeutics with \'best in class\' potential against Alzheimer´s Disease and other conformational diseases along three axes: vaccines, antibodies and small molecules. AC IMMUNE | ALZHEIMER'S DISEASE AC Immune’s therapeutic and diagnostic agents are at the forefront of fighting against one of the world’s greatest healthcare challenges – the need to develop reliable and accurate diagnostics and disease modifying treatments to improve the lives of patients suffering from Alzheimer’s and other neurodegenerative diseases. AC IMMUNE DEMONSTRATES ENHANCED PERFORMANCE OF FIRST-IN AC Immune Demonstrates Enhanced Performance of First-in-class Parkinson s Diagnostic Agent July 28, 2020 Next-generation PET tracer detects pathological alpha-synuclein with improved signal-to-noiseratio
SMALL MOLECULES TARGETING TAU PROPAGATION … Sonia Poli is an AC Immune’s employee No off-label nor investigational use of therapeutic products will be presented AC IMMUNE INITIATES PHASE 1 STUDY OF ACI-3024 SMALL Tau Morphomerâ„¢ is the focus of a partnership with Eli Lilly and Company. LAUSANNE, Switzerland, July 17, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, today announced dosing of the first subject in a Phase 1 study of ACI-3024, a first-in-class investigational oral small molecule Tau Morphomerâ„¢ inhibitor that will be NOVEL PET TRACERS OF Α-SYNUCLEIN © 2017 AC Immune. Not to be used or reproduced without permission. www.acimmune.com Novel PET Tracers of α-Synuclein for the Diagnosis of Parkinson’s Disease SYNUCLEIN PET PROJECT REPRINT FROM FEBRUARY 28, 2019 TOOLS & TECHNIQUES Synuclein PET project BY ALLISON JOHNSON, STAFF WRITER As the Parkinson’s field starts to solve the problem of how to 18F-PI-2620, CLINICAL EVALUATION OF Andrew Stephens • 18F-PI2620 Tau-PET • AAT 2018 –March 15-18, 2018 Page 2 • Andrew Stephens is an employee of Piramal Imaging GmbH (Berlin, Germany) • 18F-PI-2620 is an investigational compound • This presentation may contain forward-looking statements based on current assumptions and MORPHOMER : PLATFORM AND PIPELINE REVIEW NASDAQ: ACIU | Morphomerâ„¢Platform Event | March 2021 © 2021 AC Immune. Not to be used or reproduced without permission 2013 2014 20152017 2019
AC IMMUNE’S ALZHEIMER’S VACCINE GENERATES POTENT ANTI-PTAU PRESS RELEASE 1 / 3 AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study Interim results of ACI-35.030 vaccination show high titers of antigen-specificantibodies at
We use cookies in order to analyze traffic of this website. Your further use of this website will be considered consent. For more information visit our Cookie Policy. I agree
* About us
* Senior management team * Board of Directors * Scientific Advisory Board * Clinical Advisory Board* History
* Values
* Partners
* Science
* Roadmap to Successful Therapies for Neurodegenerative Diseases* R&D strategy
* Technology platforms * Intellectual property * Alzheimer's disease * Scientific publications * Scientific Presentations * AC Immune Key Opinion Leader (KOL) Breakfast * AD/PD 2019 Posters and Presentations * AD/PD 2018 Posters and Presentations* Pipeline
* AC Immune's robust pipeline * Our strategic vision* Media
* News features
* Press Releases
* Image gallery
* Media contact
* Email alerts
* Investors
* Overview
* Stock Information
* News
* Events & Presentations * Corporate Governance * Financial Information* Analyst Coverage
* Information Request* Investor Contact
* Email Alerts
* Join us
* Working at AC Immune * Career opportunities* Contact us
*
World-class science that makes a difference inpatients’ lives
Alleviate pain and
improve the lives of families and caregiversLeading the way in
treatment of
neurodegenerative diseases World-class science that makes a difference inpatients’ lives
Alleviate pain and
improve the lives of families and caregiversLeading the way in
treatment of
neurodegenerative diseases World-class science that makes a difference inpatients’ lives
prev
next
* About us
* Science
* Pipeline
* Media
* Investors
* Join us
* Contact us
*
At AC Immune, we are passionate about making a difference in the lives of people affected by Alzheimer’s and other neurodegenerative diseases. Our goal is to become the global leader in precision medicine of neurodegenerative diseases that are one of the biggest challenges facing society today and future generations.LATEST NEWS
JUNE 2, 2021
AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-BetaMAY 20, 2021
AC Immune to Highlight First-in-Class Alzheimer’s Disease Vaccine Programs at Upcoming Investor ConferencesMAY 17, 2021
AC Immune Announces Expansion of Phase 1b/2a phospho-Tau Alzheimer’s Vaccine Trial and Provides a Program UpdateFEATURES
FEBRUARY 10, 2021
The Covid-19 Vaccine Offers a Road Map for Tackling Dementia. Here’sHow.
FEBRUARY 9, 2021
Scrip Asks…What Does 2021 Hold For Biopharma?COMPANY INFORMATION
Discover more about us, who we are, and how we innovate to improve neurodegenerative disease understanding and develop breakthroughtherapies.
PRODUCT PIPELINE
A broad pipeline focused on neurodegenerative diseases with complementary diagnostic agents driven by proprietary technologyplatforms.
STOCK INFORMATION
Up to date company stock information and analytics directly fromNasdaq
© AC Immune 2017 | Intranet access | Contact us | Terms of use | Linkedin © AC Immune 2017 Intranet access Contact us Terms of use LinkedinDesigned by:
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0